Cellectis (NASDAQ:CLLS) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.17) by 5.88 percent. This is a 71.93 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $33.22 million which beat the analyst consensus estimate of $9.45 million by 251.59 percent. This is a 1.57K percent increase over sales of $1.99 million the same period last year.